Vitro Biopharma, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q3 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Vitro Biopharma, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q3 2012 to Q2 2024.
  • Vitro Biopharma, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending July 31, 2024 was $69.1K, a 12.9% decline year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $69.1K -$10.2K -12.9% Jul 31, 2024 10-Q 2024-09-16
Q1 2024 $157K +$110K +230% Apr 30, 2024 10-Q 2024-05-31
Q4 2023 $111K +$48.9K +78.3% Jan 31, 2024 10-Q 2024-03-14
Q3 2023 $120K +$46.1K +62.7% Oct 31, 2023 10-Q 2024-09-16
Q2 2023 $79.3K Jul 31, 2023 10-Q 2023-08-28
Q1 2023 $47.5K Apr 30, 2023 10-Q 2023-06-13
Q4 2022 $62.4K Jan 31, 2023 10-Q 2023-03-14
Q3 2022 $73.5K Oct 31, 2022 10-K 2024-01-29
Q4 2012 $2.38K Jan 31, 2013 10-Q 2013-03-21
Q3 2012 $2.38K Oct 31, 2012 10-K 2013-02-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.